New investment in Respiree
We’re thrilled to back Respiree in their US$11.6M Series A, together with ClavystBio, Adaptive Capital Partners, Mayo Clinic´s Foundation for Medical Research, Greenwillow Capital Management, Seeds Capital, and she1K.
Respiree is redefining how we monitor and manage cardio-respiratory health across the care continuum, starting in acute care hospitals. Their AI-augmented platform combines FDA-cleared, clinically validated sensors with a device-agnostic software stack to deliver real-time, longitudinal insights—from acute care to home-based recovery.
Their platform, 1Bio™, integrates data from EHRs, wearables, and mobile tools to generate high-precision risk scores, automate care pathways, and reduce alarm fatigue—empowering nurses and clinicians to make faster, more accurate decisions.
With proven performance in outperforming legacy scoring systems like EPIC’s Deterioration Index, Respiree is setting a new standard in patient monitoring. Strong partnerships with Phillips and Roche Diagnostics along with expansion across the U.S., Australia, and Asia-Pacific represents the global traction for their solution.
“We are very proud to welcome Respiree to the We VC portfolio. Respiree stands out in the market by providing a patient monitoring AI/ML +hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration. Their scientifically validated data and key partnerships position Respiree for a promising scale-up journey driven by an extremely execution focused team.”
Louise Warme, Head of We Venture Capital
For more information, please visit: